Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia.

Abstract

BACKGROUND AND AIMS:

Thrombocytopenia is a common hematological abnormality observed in patients infected with hepatitis C virus (HCV). The use of eltrombopag has been approved for HCV-associated thrombocytopenia. This is the first study aiming to determine the predictive factors of response to eltrombopag therapy in patients with HCV-associated thrombocytopenia.

PATIENTS AND METHODS:

This prospective study was carried out on 130 patients with chronic HCV-associated thrombocytopenia (<50,000×109/L) that precludes the initiation of HCV therapy. Eltrombopag was initiated at a dose of 25 mg once daily; the dose was adjusted with 25 mg increments every 2 weeks to achieve the target platelet count. The primary end point was to achieve stable target platelet count (50,000-100,000×109/L) required to initiate antiviral therapy.

RESULTS:

Treatment response was achieved in 111 (85.38%) patients. This prospective study showed that megakaryocyte hypoplasia or aplasia and splenectomy were independent risk factors for eltrombopag nonresponse in chronic HCV-associated thrombocytopenic patients.

CONCLUSION:

Eltrombopag is safe and effective for patients with HCV-associated thrombocytopenia. Bone marrow examination should be considered before initiating treatment with eltrombopag in chronic HCV-associated thrombocytopenic patients, especially in patients with splenectomy.

• Authors: Tamer A Elbedewy, Mohamed A Elsebaey, Samah A Elshweikh, Heba Elashry, Sherief Abd-Elsalam
• Journal: Therapeutics and clinical risk management (Ther Clin Risk Manag) Vol. 15 Pg. 269-274 ( 2019) ISSN: 1176-6336 [Print] New Zealand
• PMID: 30804674 (Publication Type: Journal Article)